Glancy Prongay & Murray LLP Reminds Investors of Approaching Deadline in Class Action Lawsuit Against Outset Medical, Inc. (OM) Page 1

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 28, 2024 Deadline for filing a lead plaintiff motion in the class action brought on behalf of investors who purchased or otherwise acquired securities of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) between August 1, 2022 and August 7, 2024inclusive (the “Class Period”).

If you have suffered a loss on your Outset Medical investments or would like to inquire about potential claims to recover your losses under the federal securities laws, you may submit your contact information at www.glancylaw.com/cases/Outset-Medical-Inc-1/. You may also contact Charles H. Linehan of GPM at 310-201-9150, toll-free at 888-773-9224, or by email at [email protected] to learn more about your rights.

On July 7, 2023, after the market closed, Outset Medical announced that it had received a warning letter from the FDA alleging “that certain materials . . . promote continuous renal replacement therapy (CRRT), a modality outside of the current indications for the Tablo Hemodialysis System” and “alleging that the TabloCart with prefiltration . . . requires prior 510(k) clearance for marketing authorization.” and that the company would “work with the FDA to resolve this observation, including potentially filing a 510(k) on TabloCart.” On this news, Outset Medical’s stock price fell $1.20, or 5.9%, to close at $19.26 per share on July 10, 2023, on unusually high trading volume.

On August 2, 2023, after the market close, the Company issued a press release announcing a “TabloCart Shipping Pause with Pre-Filtering Pending 510(k) Clearance.” On this news, Outset Medical’s stock price fell $1.97, or 10.18%, to close at $17.39 per share on August 3, 2023, on unusually high trading volume.

On October 12, 2023, after the market closed, the Company announced that its revenue growth had been significantly impacted by the FDA warning letter. Specifically, the Company issued a press release announcing its preliminary third quarter 2023 financial results as well as updated financial guidance for 2023 revenue, which reflected that “(g)rowth in the quarter was muted by a larger than expected impact related to the recent FDA warning letter.” On this news, the Company’s stock price fell $3.38, or 49.9%, to close at $3.39 per share on October 13, 2023, on unusually high trading volume.